[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201702082VA - Benzyl substituted indazoles as bub1 inhibitors - Google Patents

Benzyl substituted indazoles as bub1 inhibitors

Info

Publication number
SG11201702082VA
SG11201702082VA SG11201702082VA SG11201702082VA SG11201702082VA SG 11201702082V A SG11201702082V A SG 11201702082VA SG 11201702082V A SG11201702082V A SG 11201702082VA SG 11201702082V A SG11201702082V A SG 11201702082VA SG 11201702082V A SG11201702082V A SG 11201702082VA
Authority
SG
Singapore
Prior art keywords
benzyl substituted
substituted indazoles
bub1 inhibitors
bub1
inhibitors
Prior art date
Application number
SG11201702082VA
Inventor
Anne Mengel
Hans-Georg Lerchen
Manfred Möwes
Thomas Müller
Lars Bärfacker
Marion Hitchcock
Arwed Cleve
Joachim Kuhnke
Hans Briem
Gerhard Siemeister
Wilhelm Bone
Amaury Ernesto Fernandez-Montalvan
Jens SCHRÖDER
Ursula Mönning
Simon Holton
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201702082VA publication Critical patent/SG11201702082VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201702082VA 2014-09-19 2015-09-17 Benzyl substituted indazoles as bub1 inhibitors SG11201702082VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185604 2014-09-19
EP15176903 2015-07-15
PCT/EP2015/071340 WO2016042084A1 (en) 2014-09-19 2015-09-17 Benzyl substituted indazoles as bub1 inhibitors

Publications (1)

Publication Number Publication Date
SG11201702082VA true SG11201702082VA (en) 2017-04-27

Family

ID=54140475

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702082VA SG11201702082VA (en) 2014-09-19 2015-09-17 Benzyl substituted indazoles as bub1 inhibitors

Country Status (27)

Country Link
US (1) US10350206B2 (en)
EP (1) EP3194379A1 (en)
JP (1) JP6664385B2 (en)
KR (1) KR20170049604A (en)
CN (1) CN107001331A (en)
AP (1) AP2017009803A0 (en)
AU (1) AU2015316796A1 (en)
BR (1) BR112017005444A2 (en)
CA (1) CA2961589A1 (en)
CL (1) CL2017000654A1 (en)
CO (1) CO2017002532A2 (en)
CR (1) CR20170100A (en)
CU (1) CU20170029A7 (en)
DO (1) DOP2017000078A (en)
EA (1) EA032401B1 (en)
EC (1) ECSP17016797A (en)
IL (1) IL251071A0 (en)
MA (1) MA39484A (en)
MX (1) MX2017003664A (en)
NI (1) NI201700034A (en)
PE (1) PE20170697A1 (en)
PH (1) PH12017500509A1 (en)
SG (1) SG11201702082VA (en)
TN (1) TN2017000092A1 (en)
TW (1) TW201615636A (en)
UY (1) UY36311A (en)
WO (1) WO2016042084A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (en) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт SUBSTITUTED BENZILINDASOLS FOR THE APPLICATION OF BUB1-KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
LT3495367T (en) 2012-06-13 2021-02-25 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
EP3010901B1 (en) 2013-06-21 2017-09-13 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
JP2016525076A (en) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト Substituted benzylpyrazoles
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
LT3406609T (en) 2014-02-06 2024-09-25 Nxera Pharma Uk Limited Bicyclic aza compounds as muscarinic receptor agonists
ES2708211T3 (en) 2014-06-17 2019-04-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
US10350206B2 (en) 2014-09-19 2019-07-16 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as BUB1 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
US11242335B2 (en) 2017-04-11 2022-02-08 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3788046A1 (en) 2018-05-04 2021-03-10 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022552324A (en) 2019-10-14 2022-12-15 インサイト・コーポレイション Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CN115151539A (en) 2019-12-04 2022-10-04 因赛特公司 Derivatives of FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
EE9900151A (en) 1996-10-14 1999-12-15 Bayer Aktiengesellschaft Heterocyclylmethyl-substituted pyrazole derivatives
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19846514A1 (en) 1998-10-09 2000-04-20 Bayer Ag New arylmethyl and heterocyclylmethyl substituted heteroaryl-indazole derivatives useful in treatment of cardiovascular, ischemic and urogenital disorders
ES2295441T3 (en) 2001-12-18 2008-04-16 MERCK & CO., INC. MODULATORS OF PIRAZOL HETEROARIL REPLACED 5 METABOTROPIC RECEIVER OF GLUTAMATE.
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
JP2006503043A (en) 2002-09-10 2006-01-26 サイオス インク. TGFβ inhibitor
DE10244810A1 (en) 2002-09-26 2004-04-08 Bayer Ag New morpholine-bridged indazole derivatives
US8748601B2 (en) 2003-04-11 2014-06-10 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2005070900A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (en) 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
US8796253B2 (en) 2007-05-18 2014-08-05 Bayer Intellectual Property Gmbh Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP2010111624A (en) 2008-11-06 2010-05-20 Shionogi & Co Ltd Indazole derivative having ttk inhibitory action
JP5580332B2 (en) 2008-12-18 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Substituted indazole derivatives active as kinase inhibitors
CN102666537A (en) 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 Azaindazoles to treat flaviviridae virus infection
CA2936852C (en) 2009-11-27 2019-10-29 Adverio Pharma Gmbh Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
RU2017144535A (en) 2010-03-30 2019-02-18 Версеон Корпорейшн MULTI-DISPLACED AROMATIC COMPOUNDS AS THROMBINE INHIBITORS
AR088020A1 (en) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc HETEROCICLICAL COMPOUNDS AS SGC STIMULATORS
UA111754C2 (en) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт SUBSTITUTED BENZILINDASOLS FOR THE APPLICATION OF BUB1-KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
ES2638144T3 (en) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
CN106117194A (en) 2011-12-27 2016-11-16 铁木医药有限公司 Can be used as 2 benzyls of SGC stimulant, 3 (pyrimidine 2 base) substituted pyrazoles
EP2847180B1 (en) 2012-05-11 2017-01-04 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
CA2907594A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
JP2016514718A (en) 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト 3-heteroaryl substituted indazoles
WO2014147144A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
JP2016522232A (en) 2013-06-21 2016-07-28 バイエル ファーマ アクチエンゲゼルシャフト Heteroaryl-substituted pyrazoles
JP2016525076A (en) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト Substituted benzylpyrazoles
JP2016522231A (en) 2013-06-21 2016-07-28 バイエル ファーマ アクチエンゲゼルシャフト Diaminoheteroaryl substituted pyrazoles
CA2916097A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
EP3010901B1 (en) 2013-06-21 2017-09-13 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
PE20170937A1 (en) 2014-09-19 2017-07-13 Glaxosmithkline Ip Dev Ltd NEW ACTIVATORS OF SOLUBLE GUANILATE CYCLASE AND ITS USE
CN107074825A (en) 2014-09-19 2017-08-18 拜耳制药股份公司 The indazole compounds replaced as the benzyl of BUB1 kinase inhibitors
CN107148420A (en) 2014-09-19 2017-09-08 拜耳制药股份公司 The indazole compounds of benzyl substitution
EP3194380A1 (en) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
CN107001328B (en) 2014-09-19 2020-06-05 福马治疗股份有限公司 Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors
US10350206B2 (en) 2014-09-19 2019-07-16 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as BUB1 inhibitors
AU2015319791A1 (en) 2014-09-19 2017-02-23 Nestec Sa Treatment of cancer with alpha-amylase inhibitor in companion animals
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Also Published As

Publication number Publication date
CR20170100A (en) 2017-04-24
TN2017000092A1 (en) 2018-07-04
NI201700034A (en) 2017-06-16
IL251071A0 (en) 2017-04-30
TW201615636A (en) 2016-05-01
CL2017000654A1 (en) 2017-12-11
PH12017500509A1 (en) 2017-08-30
WO2016042084A1 (en) 2016-03-24
CN107001331A (en) 2017-08-01
EA201790649A1 (en) 2017-09-29
MA39484A (en) 2016-03-24
UY36311A (en) 2016-04-29
EA032401B1 (en) 2019-05-31
US20170273980A1 (en) 2017-09-28
PE20170697A1 (en) 2017-06-24
MX2017003664A (en) 2017-07-13
US10350206B2 (en) 2019-07-16
CO2017002532A2 (en) 2017-07-11
CU20170029A7 (en) 2017-08-08
CA2961589A1 (en) 2016-03-24
JP6664385B2 (en) 2020-03-13
KR20170049604A (en) 2017-05-10
BR112017005444A2 (en) 2018-04-24
EP3194379A1 (en) 2017-07-26
DOP2017000078A (en) 2017-06-30
JP2017530962A (en) 2017-10-19
AU2015316796A1 (en) 2017-03-30
AP2017009803A0 (en) 2017-03-31
ECSP17016797A (en) 2017-05-31

Similar Documents

Publication Publication Date Title
IL287113A (en) Smyd inhibitors
IL251071A0 (en) Benzyl substituted indazoles as bub1 inhibitors
HK1244792B (en) Necrosis inhibitors
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
HK1243415A1 (en) Bromodomain inhibitors
EP3116503A4 (en) Hptp-beta inhibitors
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
HK1244480A1 (en) Necrosis inhibitors
IL246400A0 (en) Neprilysin inhibitors
ZA201606174B (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
IL265139B (en) Dopamine-b-hydroxylase inhibitors
IL250306A0 (en) Indazoles
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
GB201501004D0 (en) Inhibitors
GB201612860D0 (en) Inhibitors
GB201400299D0 (en) Corrosion inhibitors
EP3628374C0 (en) Bcl-3 inhibitors
PT3151658T (en) Horseshoe
HK1232214A1 (en) Hexahydrofuropyrroles as pde1 inhibitors pde1
GB201520949D0 (en) Inhibitors
GB201401005D0 (en) Inhibitor
EP3180003A4 (en) Pkc-epsilon inhibitors
GB201418154D0 (en) Inhibitors